English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

━━ Objective. Tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)induces apoptosis in various in vitro tumor studies. However de novo expression of TRAIL and TRAIL-receptor 1(TRAIL-R1)in cancer tissues is not well documented, and few data are available on their effect on the clinical outcome of non-small cell lung cancer (NSCLC)patients. The aim of this study was to evaluate the expression of TRAIL and TRAIL-R1 proteins in cancer tissues surgically resected from patients with NSCLC by scoring the immunoreactivity, and to examine the correlation between the expression of these proteins and clinical findings of NSCLC. Methods. Cancer tissues and normal tissues were obtained from patients with NSCLC. The expression of TRAIL and TRAIL-R1 proteins was examined by immunohistochemical studies. Results. Significantly higher immunostaining scores for TRAIL and TRAIL-R1 were observed in cancer tissues compared with normal tissues of patients with NSCLC(P<0.0001 for both). There was a significantly positive correlation between the immunostaining score of TRAIL or TRAIL-R1 and pathological T-factor in these patients(P=0.021 and P=0.009, respectively). Conclusion. The majority of NSCLCs expressed TRAIL and TRAIL-R1, which may play a role in regulating the progression of NSCLC. (JJLC. 2006;46:321-327)

haigan

Expression of TNF-related Apoptosis-inducing Ligand (TRAIL) and TRAIL Receptor 1 on Cancer and Normal Tissues in Patients with Non-small Cell Lung Cancer